Related Experiment Video
Updated: Jan 19, 2026
09:43
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
Published on: January 14, 2014
8.4K
Pleomorphic xanthoastrocytoma: a brief review
Nawal Shaikh1, Nupur Brahmbhatt2, Tim J Kruser3,4
1Department of Neurology, University of Mississippi Medical Center, 2500 N. State Street, Jackson, MS 39216, USA.
CNS Oncology
|September 20, 2019
Summary
Pleomorphic xanthoastrocytoma (PXA) is a rare brain tumor. BRAF mutations are key to understanding PXA
Area of Science:
- Neuro-oncology
- Molecular pathology
- Tumorigenesis
Background:
- Pleomorphic xanthoastrocytoma (PXA) is a rare primary central nervous system (CNS) tumor.
- Advances in molecular characterization are crucial for defining tumor subtypes.
- Understanding PXA pathophysiology is essential for improved patient outcomes.
Purpose of the Study:
- To review the clinical presentation and radiographic appearance of PXA.
- To discuss the pathology, including molecular findings.
- To summarize current therapeutic strategies for PXA.
Main Methods:
- Literature review of clinical, pathological, and molecular data.
- Analysis of BRAF mutations in PXA.
- Synthesis of information on surgical, radiotherapeutic, and systemic treatments.
Main Results:
- BRAF mutations are identified in a significant proportion of PXA cases.
- Molecular findings provide insights into PXA pathophysiology.
- PXA exhibits a wide spectrum of clinical behavior.
Conclusions:
- BRAF mutations have significant prognostic and therapeutic implications for PXA.
- A comprehensive understanding of PXA requires integrating clinical, pathological, and molecular data.
- Further research into targeted therapies is warranted.
